Prelude Therapeutics Incorporated
PRLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $7 | $0 | $0 | $4 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $6 | $0 | $0 | $4 |
| % Margin | 93.5% | – | – | 100% |
| R&D Expenses | $22 | $26 | $29 | $32 |
| G&A Expenses | $0 | $6 | $6 | $6 |
| SG&A Expenses | $5 | $6 | $6 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $26 | $32 | $35 | $38 |
| Operating Income | -$20 | -$32 | -$35 | -$34 |
| % Margin | -314.1% | – | – | -845.8% |
| Other Income/Exp. Net | $1 | $1 | $3 | $5 |
| Pre-Tax Income | -$20 | -$31 | -$32 | -$29 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$20 | -$31 | -$32 | -$29 |
| % Margin | -303.5% | – | – | -718.3% |
| EPS | -0.26 | -0.41 | -0.42 | -0.38 |
| % Growth | 36.6% | 2.4% | -10.5% | – |
| EPS Diluted | -0.26 | -0.41 | -0.42 | -0.38 |
| Weighted Avg Shares Out | 76 | 76 | 76 | 76 |
| Weighted Avg Shares Out Dil | 76 | 76 | 76 | 76 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$19 | -$32 | -$34 | -$33 |
| % Margin | -296.9% | – | – | -833.6% |